Predicted Expenditure for Prescription Drugs for Multiple Sclerosis in the Italian Market Between 2023 and 2028: Results of the Oracle Project.
Damiano PaolicelliGiovanna BorrielloRaffaella ClericiElena ColomboDavide CroceEmanuele D'AmicoNicola De RossiAlessia Di SapioGiuseppe FenuDavide MaimoneGirolama A MarfiaMarcello MocciaPaola PeriniMaria G PiscagliaLorenzo RazzoliniMassimo RiccaboniElisabetta SignorielloGianluca AgostoniAlberto FarinaMargaret MondinoFrancesco BerrutoAlessia TettamantiFrancesca DonnalojaCarla TortorellaPublished in: Neurology and therapy (2024)
Despite the increase in the number of patients treated for MS and the launch of new molecules that will reach high market penetration, the model confirmed sustainability for the Italian National Healthcare Service.